Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404804 | 0.91 | BCHE (0.41) | PTPN1BCHEMEN1USP2POLB | |
| SCHEMBL4402919 | 0.89 | PTPN1 (0.38) | PTPN1BCHEMEN1USP2POLB | |
| SCHEMBL4403646 | 0.83 | SLC6A2 (0.36) | PTPN1BCHEANTXR2 | |
| SCHEMBL17612542 | 0.78 | ANTXR2 (0.53) | PTPN1MEN1USP2POLBKMT2A | |
| SCHEMBL4292941 | 0.78 | PTPN1 (0.48) | PTPN1MEN1USP2POLBKMT2A | |
| SCHEMBL23348434 | 0.78 | BCHE (0.49) | PTPN1BCHEMEN1USP2POLB | |
| SCHEMBL14208566 | 0.78 | BCHE (0.49) | PTPN1BCHEMEN1USP2POLB | |
| SCHEMBL14413573 | 0.78 | BCHE (0.49) | PTPN1BCHEMEN1USP2POLB | |
| SCHEMBL21886718 | 0.78 | BCHE (0.49) | PTPN1BCHEMEN1USP2POLB | |
| SCHEMBL19944547 | 0.78 | BCHE (0.49) | PTPN1BCHEMEN1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173606-B2 | Sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LIMITED (AU) | 2012-05-08 | — | — | US | disclosed |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | HPSE, APOB, LIPG | PTPN1 612/4885BCHE 2364/4885MEN1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.